rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMCR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Immunocore at UBS Global Biopharma Conference 2026: KIMMTRAK drives growth
      Nov 17Investing.comIMCRUBS
      Immunocore Holdings plc (IMCR) Presents at Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting - Slideshow (NASDAQ:IMCR) 2026-11-10

      2026-11-10. The following slide deck was published by Immunocore Holdings plc in conjunction with this event.

      Nov 10Seeking AlphaIMCR
      Immunocore to present at upcoming investor conferences

      (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November. UBS Global Biopharma Conference 2026Fireside Chat: Tues

      Nov 9Yahoo FinanceIMCR
      Immunocore Holdings ADR earnings missed by $0.16, revenue fell short of estimates
      Nov 6Investing.comIMCR
      Immunocore reports phase 1 data for uveal melanoma combination
      Nov 6Investing.comIMCR
      Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
      Nov 6Yahoo FinanceIMCR
      Immunocore reports third quarter financial results and provides a business update
      Nov 6Yahoo FinanceIMCR
      Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
      Oct 29Yahoo FinanceIMCR
      Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?
      Oct 29Yahoo FinanceIMCR
      Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
      Oct 15Yahoo FinanceIMCR
      Immunocore Doses First Patient in Phase 1 Trial of Type 1 Diabetes Therapy
      Oct 15Yahoo FinanceIMCR
      Immunocore Holdings stock hits 52-week low at 27.5 USD
      Oct 14Investing.comIMCR
      Immunocore Hldgs Q2 2026 Earnings Call Transcript - Immunocore Holdings (NASDAQ:IMCR)

      Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to

      Oct 5BenzingaIMCR
      Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial (NASDAQ:IMCR)
      Sep 29Seeking AlphaIMCR
      Immunocore: KIMMTRAK Nearly Covers The Valuation Before A Major Phase 3 Readout (NASDAQ:IMCR)
      Sep 25Seeking AlphaIMCR
      Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

      IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.

      Sep 15Yahoo FinanceIMCR
      Immunocore at Morgan Stanley conference: kimmtrak drives growth
      Sep 14Investing.comIMCRMS
      Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

      Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve

      Sep 14Yahoo FinanceIMCR
      Immunocore Completes Enrollment in Study of Potential Advanced Melanoma Treatment

      Immunocore (IMCR) achieved its target enrollment of 540 patients in a phase 3 clinical trial evaluat

      Sep 14Yahoo FinanceIMCR
      Immunocore at cantor global healthcare conference: growth, trials and cash
      Sep 10Investing.comIMCR
      Immunocore to present at upcoming investor conferences
      Sep 1Yahoo FinanceIMCR
      Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

      Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.

      Aug 25Yahoo FinanceIMCR
      Exclusive BAC Article: Immunocore Holdings; KIMMTRAK 18% Revenue Growth, CM Expansion Data End 2026, Adjuvant Uveal Melanoma As Further Expansion, And Catalysts (NASDAQ:IMCR)
      Aug 24Seeking AlphaIMCR

      This is the newest page. Registered accounts read further back.